The Effect of a Liraglutide on IVF in Obese PCOS

NCT03353948 on ClinicalTrials.gov · last registry update 2017-11-27

A small phase 4 — 30 participants, against a typical 75. The sponsor logged completion for 31 May 2016. Primary outcome, as filed: IVF pregnancy rates. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University Medical Centre Ljubljana
Sponsor type: Other
Enrollment: 30
Started: 2014-09-01
Primary completion: 2016-05-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

IVF pregnancy rates

Conditions studied

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.